

## PD-L1 Protein, Mouse (HEK293, His)

<b>Cat. No.:</b>	HY-P70632
<b>Synonyms:</b>	Programmed cell death 1 ligand 1Cd274; programmed cell death 1 ligand 1; PD-L1; PDCD1 ligand 1; programmed death ligand 1; B7 homolog 1; B7-H1; CD274
<b>Species:</b>	Mouse
<b>Source:</b>	HEK293
<b>Accession:</b>	Q9EP73 (F19-T238)
<b>Gene ID:</b>	60533
<b>Molecular Weight:</b>	38-58 kDa

### PROPERTIES

<b>AA Sequence</b>	<pre> FTITAPKDLV   VVEYGSNVTM   ECRFPVEREL   DLLALVYWE KEDEQVIQFV   AGEEDLKPQH   SNFRGRASLP   KDQLLKGNAA LQITDVKLQD   AGVYCCIIISY   GGADYKRITL   KVNAPYRKIN QRISVDPATS   EHELICQAEG   YPEAEVIWTN   SDHQPVSGKR SVTTSRTEGM   LLNVTSSLRV   NATANDVFYC   TFWRSQPGQN HTAELIIPEL   PATHPPQNRRT           </pre>
<b>Biological Activity</b>	Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated CTLL-2 mouse cytotoxic T cells. The ED <sub>50</sub> this effect is 0.8023 µg/mL, corresponding to a specific activity is 1246.42 units/mg
<b>Appearance</b>	Lyophilized powder.
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution of 20 mM PB, 150 mM NaCl, pH 7.4.
<b>Endotoxin Level</b>	<1 EU/µg, determined by LAL method.
<b>Reconstitution</b>	It is not recommended to reconstitute to a concentration less than 100 µg/mL in ddH <sub>2</sub> O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).
<b>Storage &amp; Stability</b>	Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
<b>Shipping</b>	Room temperature in continental US; may vary elsewhere.

### DESCRIPTION

<b>Background</b>	PD-L1 protein plays a crucial role in maintaining immune tolerance to self by acting as a ligand for the inhibitory receptor PDCD1/PD-1. This interaction modulates the activation threshold of T-cells, limiting their effector response and potentially stimulating T-cell subsets that produce interleukin-10 (IL10). However, tumors exploit the PDCD1-mediated inhibitory
-------------------	--

---

pathway to attenuate anti-tumor immunity and evade destruction by the immune system, thereby promoting tumor survival. The interaction between PD-L1 and PDCD1/PD-1 inhibits the function of cytotoxic T lymphocytes (CTLs), but blocking this pathway can reverse the exhausted T-cell phenotype and normalize the anti-tumor response, offering a promising strategy for cancer immunotherapy.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA